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Stransfemoral (TF) route in the catheterization laboratory (C-TF) or hybrid room
(OR-TF) and OR non-TF TAVR.
Methods: A retrospective study was performed on 174 patients who underwent
TAVR at a single US academic institution using the SAPIEN valve from 11/2011 to 4/
2013. Patients were stratiﬁed into 3 groups: C-TF TAVR (n¼51), OR-TF TAVR
(n¼39), and OR-non-TF TAVR (n¼84). All C-TF patients were performed with i.v.
sedation and TTE. The OR-TF and OR-non-TF patients were performed in the hybrid
OR with general anesthesia and TEE. Total variable cost, hospital payment, and
contribution margin were utilized to determine the ﬁnancial viability of TAVR.
Results: Compared to OR-TF and OR-non-TF, C-TF had a signiﬁcantly lower
procedure time (p<0.001) and postop ventilator hours (p<0.001). Resource utilization
in terms of ICU (p<0.001), postop (p<0.001), and total hospital LOS (p<0.001) was
signiﬁcantly higher in OR-non-TF patients. Total variable cost in the OR-non-TF
TAVR was the highest ($57,19723,142), but hospital payment was comparably the
highest ($62,64758,826); leading to the highest contribution margin
($19,59443,553). Total variable cost and hospital payment were lowest in the C-TF
group, leading to a contribution margin of $15,52919,556 (Table).30 days
p-value
1 year *
p-value
< 90 years  90 years < 90 years  90 years
no of pacients (%) no patients (%)
All cause-
death
8.4% 10.4% 0.59 18.9 18.8% 0.87
Cardiovascular
death
7% 6.2% 0.99 12.4% 10.4% 0.64
Stroke 3.8% 4.2% 0.70 5.4% 8.3% 0.52
Death/
stroke
8.6% 8.3% 0.99 21.9% 27.1% 0.46
Major
bleeding
16.5% 10.4% 0.28 17.6% 10.4% 0.21
Safety
endpoint**
21.6% 20.8% 0.90 - - -
All clinical events were adjudicated according to VARC-2 criteria.
* Kaplan-Meier estimates .
** Composite of death, stroke, major bleeding, renal insufﬁciency, major vascular
complication, re-intervention or repeat surgery.
Table. Admission Resource Use and Costs
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OR time, min 160  85 229  70 234  49 <0.001
Ventilator hours 1.7  10.1 23.4  66.7 48.4  131.0 <0.001
ICU LOS, hrs 21.9  17.7 50.5  64.1 98.3  138.2 <0.001
Post-op LOS, days 3.7  2.7 4.7  3.2 9.1  7.5 <0.001
Total hospital LOS 6.0  4.9 7.1  5.7 11.2  8.5 <0.001
Total variable
cost
$45,173 
16,988
$52,268 
16,480
$57,197 
23,142
<0.001
Hospital payment $45,412 
28,158
$59,931 
20,954
$62,647 
58,826
0.002
Contribution
margin
$15,529 
19,556
$10,421 
20,389
$19,594 
43,553
0.27
All values are meanSD; all cost data is in $US.Conclusions: This is the ﬁrst study comparing the economic impact of the minimalist
and standard approaches to TAVR. The economic beneﬁts of TAVR in all groups
were shown to be ﬁnancially viable (positive contribution margin). Resource utili-
zation was the least in the C-TF group, but hospital reimbursement was also the
lowest. A more deﬁned reimbursement strategy for these high-risk patients is required.
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Background: Trans-femoral (TF) approach represents the ﬁrst choice of vascular
access for transcatheter aortic valve replacement (TAVR). When not feasible, alter-
native approaches such as axillary artery (TA) or, more recently, direct ascending
aorta (DA) are used for self-expandable valve implantation. Aim of this work was to
evaluate the safety of TAVR with self-expandable valve through these alternative
vascular approaches in  85 years old patients (pts).
Methods: From the Clinical Service (former Italian CoreValve Registry) dataset,
1317 consecutive pts underwent TAVR with 3 generation CoreValve in 7 Italian sites
between June 2007 and November 2012, were included in this analysis. Pts were
divided into two groups according to the vascular access: TF or alternative approaches
(TA and DA). Primary end point was the 30-day safety evaluation according to
VARC-2 criteria.
Results: Four hundred and eighty-four pts (37%) had an age  85 years (range,
85-99). TF access was used in 81% and alternative approaches in 19% of cases (16%
TA and 2.5% DA). Sex female was higher in TF (64% vs 50%, respectively, p¼0.014)
while the Logistic Euroscore I was higher in the second group (21% vs 26%,B236 JACC Vol 62/18/Suppl B j October 27–Novemberrespectively, p¼0.039), as well as the presence of coronary artery disease (41% vs
58%, p¼0.004) and history of myocardial infarction (14% vs 23%, respectively,
p¼0.036). There was non signiﬁcant difference regarding to devices success between
two approaches (95% vs 96%, respectively, p¼0.8). Combined early safety end point
was similar between two groups (28% vs 22%, respectively, p¼0.23), as well as the
individual components, except for a signiﬁcant higher incidence of acute kidney injury
(stage II- III) in TF compared to alternative accesses (30% vs 17%, respectively,
p¼0.010). All-cause of death and cardiovascular death at 30 days and 1 year of follow
up were similar into two groups irrespective of different type of vascular access.
Conclusions: When TF approach was not feasible because of anatomical reasons, the
alternative approach such as axillary artery (TA) or, more recently, direct ascending
aorta (DA) could lead to a self-expandable valve implantation safely also in elderly
patients.
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Background: Transcatheter aortic valve implantation (TAVI) has been established as
a standard treatment in inoperable and high-risk elderly pts with severe aortic stenosis.
However, there is no data thus far assessing the safety and the efﬁcacy of TAVI in pts
older than 90 years. We therefore sought to evaluate the early- and long-term clinical
outcomes in nonagenarian pts undergoing TAVI.
Methods: Between January 2008 and February 2013, pts with symptomatic severe
aortic stenosis underwent and were enrolled in the Brazilian multicenter registry.
Among a total of 418 pts, 370 were < 90 years and 48 (13%) were nonagenarian.
Results: Nonagenarian pts were 12 years older than pts < 90 years (92.4 years vs.
80.12 years; p<0.001). Compared with pts < 90 years, nonagenarian pts had higher
STS risk score (19.4413.84% vs. 14.0312.38%; p¼0.005), lower body mass index
(24.553.40 vs. 26.314.61 kg/m2; p¼0.01), but higher baseline left ventricular
ejection fraction (61.7412.32% vs. 57.27%15.60%, p¼0.03). 30-day and 1-year
main clinical outcomes are presented in Table.Conclusions: In this real world Brazilian registry, nonagenarian pts who underwent
TAVI had favorable and similar early- and long-term clinical outcomes as compared
with pts < 90 years. The treatment of symptomatic severe aortic stenosis in nona-
genarians pts with TAVI deemed to be a non-futility approach.1, 2013 j TCT Abstracts/POSTER/Aortic Valve Disease and Treatment
